• Comparative Antibacterial Efficacy of Cefoperazone and New β

  2026-05-26

  Cullmann et al. conducted a comprehensive comparison of N-formimidoyl thienamycin (MK0787) and several recently developed β-lactam antibiotics, including cefoperazone, against a diverse set of resistant clinical isolates. Their findings provide nuanced insights into the relative strengths of these agents against gram-negative and gram-positive pathogens, informing the selection and design of antimicrobial studies.

• Acetylcysteine in 3D Tumor-Stroma Models: Protocols & Insigh

  2026-05-25

  Acetylcysteine (N-acetyl-L-cysteine) empowers next-generation research into chemoresistance and redox modulation in 3D co-culture systems. This guide details optimized workflows, advanced troubleshooting, and actionable protocol enhancements for leveraging APExBIO’s Acetylcysteine in complex disease modeling.

• LY2228820: Precision p38 MAP Kinase Inhibitor for Advanced R

  2026-05-25

  LY2228820 offers exceptional selectivity and potency for targeted inhibition of the p38 MAPK pathway, making it a cornerstone tool in anti-inflammatory and cancer research. Explore optimized workflows, troubleshooting strategies, and protocol enhancements that unlock the full experimental potential of this ATP-competitive inhibitor.

• Cardiogreen (Indocyanine Green): Applied Protocols and PDT I

  2026-05-24

  Cardiogreen (Indocyanine Green) stands out for robust vascular imaging and advanced photodynamic therapy, ensuring precise diagnostics and targeted apoptosis induction. This guide translates recent research breakthroughs into actionable protocols, troubleshooting strategies, and new frontiers in immuno-oncology, with APExBIO’s high-purity dye as your foundation.

• Photothermal Therapy and CD47 Blockade Synergy in OSCC

  2026-05-23

  This study demonstrates that combining photothermal therapy (PTT) with CD47 immune checkpoint blockade in oral squamous cell carcinoma (OSCC) leads to markedly enhanced anti-tumor macrophage activity. The dual approach works by inducing calreticulin exposure and remodeling the tumor extracellular matrix, overcoming barriers to immune infiltration and opening new avenues for immunotherapeutic intervention.

• Forskolin as an Adenylate Cyclase Activator: Applied Workflo

  2026-05-22

  Forskolin is a benchmark adenylate cyclase activator, unlocking precise control of cAMP signaling across stem cell differentiation, inflammation, and neuroendocrine research. This article details actionable protocols, troubleshooting, and domain-bridging innovations powered by APExBIO’s high-purity Forskolin.

• THZ1: Covalent CDK7 Inhibitor Benchmarking in T-ALL Research

  2026-05-22

  THZ1 is a potent covalent CDK7 inhibitor with nanomolar efficacy and selective, irreversible binding. It disrupts transcription regulation by targeting CDK7 and shows pronounced antitumor activity in T-cell acute lymphoblastic leukemia models, according to multiple peer-reviewed and product sources.

• Preserving Native Protein Function: Strategic Insights for T

  2026-05-21

  This thought-leadership article explores the mechanistic underpinnings and strategic value of native protein gel electrophoresis for acidic proteins, with a focus on the APExBIO Basic Protein Native PAGE Gel Preparation and Electrophoresis Kit (PI ≤ 7.0). Integrating protocol guidance, competitive landscape analysis, and translational perspectives drawn from recent CFTR research, the discussion advances beyond standard product overviews to offer actionable insights for accelerating therapeutic discovery.

• Quercetin Inhibits Ferroptosis to Alleviate Liver Injury in

  2026-05-21

  This study demonstrates that quercetin directly inhibits the ACSL4/LPCAT3/ALOX15 pathway, reducing ferroptosis-mediated liver injury in Wilson’s disease models. The work reveals a novel mechanism for quercetin as a ferroptosis modulator, with implications for targeted intervention in metal toxicity-associated hepatic disorders.

• IWP-L6: Precision Porcupine Inhibitor for Wnt Pathway Studie

  2026-05-20

  IWP-L6 delivers sub-nanomolar Porcupine inhibition, enabling precise control of Wnt signaling in diverse experimental systems. Its stability and validated workflows make it the ideal tool for dissecting Wnt-dependent processes like bone formation, regeneration, and metabolic rewiring.

• M344 (SKU A4105): Precision HDAC Inhibition for Cancer Resea

  2026-05-20

  This article explores how M344 (SKU A4105), a potent histone deacetylase inhibitor, addresses real-world challenges in cell viability, proliferation, and differentiation assays. Scenario-driven Q&A blocks offer practical, evidence-backed guidance for optimizing workflows in oncology and HIV-1 latency research, emphasizing reproducibility and vendor reliability.

• Vorinostat: HDAC Inhibitor Workflows for Oncology Research

  2026-05-19

  Vorinostat (suberoylanilide hydroxamic acid) enables high-precision epigenetic modulation and apoptosis mapping in cancer biology. Discover advanced workflows, troubleshooting strategies, and comparative insights to maximize research impact using this potent HDAC inhibitor.

• Sodium Picosulfate: Enhanced Workflows for Gut–Brain Axis Mo

  2026-05-19

  Sodium Picosulfate empowers reliable modeling of water and electrolyte dynamics in preclinical gut–liver–brain axis research, supporting advanced neuroinflammation and constipation studies. APExBIO’s high-purity formulation enables reproducible results and seamless integration into both in vitro and in vivo protocols.

• BODIPY 581/591 C11: Ratiometric Fluorescent Probe for Lipid

  2026-05-18

  BODIPY 581/591 C11 enables precise, ratiometric detection of lipid peroxidation and antioxidant capacity in live cells and model membranes. Its unique emission shift and high specificity for oxygen radicals streamline workflows in oxidative stress and ferroptosis research, offering robust quantitative insights where other indicators fall short.

• Rucaparib (AG-014699, PF-01367338): Assay Optimization & Dat

  2026-05-18

  This article addresses real-world laboratory challenges in DNA damage response and cancer biology research, focusing on the rigorous application of Rucaparib (AG-014699, PF-01367338), SKU A4156. Scenario-driven analysis demonstrates how this potent PARP1 inhibitor from APExBIO enhances reproducibility, assay sensitivity, and workflow reliability in cell-based experiments.

3584 records 13/239 page Previous Next First page 上5页 1112131415 下5页 Last page